Characteristics of clinically classified IM nonresponders with primary and secondary resistance
| Characteristics . | Primary resistance . | Secondary resistance . | P* . |
|---|---|---|---|
| Quantitative features | |||
| WBC at diagnosis | Range: [32.2, 536]; mean, 195; CI: [39.8, 350] | Range: [122, 480] mean, 221; CI: [36.7, 406] | .79 |
| Age, y | Range: [43, 77]; mean, 58; CI: [49.6, 66.4] | Range: [29,66]; mean, 51.6; CI: [34.2, 69.0] | .41 |
| Mutant BCR-ABL transcripts, percentage | Range: [18, 35]; mean, 25.8; CI: [13.5, 38.0] | Range: [9, 40]; mean, 22.6; CI: [8.48, 36.7] | .64† |
| NA | 4 (28.6%) | 0 | |
| No. of colonies as percentage of untreated cells CFC IM 1μM | Range: [41.1, 67]; mean, 54.1; CI: [47.1, 61.1] | Range: [40.6, 92] mean=70.9; CI: [44.3, 97.4] | .16 |
| CFC IM 5μM | Range: [36, 56.6]; mean, 47.7; CI: [43.0, 52.5] | Range: [34, 64]; mean, 50.3; CI: [36.0, 64.7] | .66 |
| CFC IM 10μM | Range: [29.1, 61.3]; mean, 44.1; CI: [34.9, 53.3] | Range: [20.8, 60.3]; mean, 43.8; CI: [21.0, 66.5] | .97 |
| Time from diagnosis to IM treatment, d | Range: [7, 302]; mean, 127.4; CI: [12.0, 178.5] | Range: [13, 377]; mean, 127; CI: [-66.7, 321] | .70 |
| Qualitative features | |||
| Sokal risk score | .434‡ | ||
| High | 5 (55.6%) | 0 | |
| Intermediate | 3 (33.3%) | 3 (60%) | |
| Low | 1 (11.1%) | 1 (20%) | |
| NA | 0 | 1 (20%) | |
| Sex | .21§ | ||
| Female | 5 (55.6%) | 1 (20%) | |
| Male | 4 (44.5%) | 4 (80%) | |
| Prior interferon | .247§ | ||
| No | 8 (88.9) | 3 (60%) | |
| Yes | 1 (11.1%) | 2 (40%) | |
| Prior hydroxyurea | 1§ | ||
| No | 9 (100%) | 5 (100%) | |
| Yes | 0 | 0 | |
| Daily IM dose | .177‡ | ||
| 400 mg | 6 (66.7%) | 2 (40%) | |
| 400-600 mg | 3 (33.3%) | 1 (20%) | |
| 400-800 mg | 0 | 2 (40%) |
| Characteristics . | Primary resistance . | Secondary resistance . | P* . |
|---|---|---|---|
| Quantitative features | |||
| WBC at diagnosis | Range: [32.2, 536]; mean, 195; CI: [39.8, 350] | Range: [122, 480] mean, 221; CI: [36.7, 406] | .79 |
| Age, y | Range: [43, 77]; mean, 58; CI: [49.6, 66.4] | Range: [29,66]; mean, 51.6; CI: [34.2, 69.0] | .41 |
| Mutant BCR-ABL transcripts, percentage | Range: [18, 35]; mean, 25.8; CI: [13.5, 38.0] | Range: [9, 40]; mean, 22.6; CI: [8.48, 36.7] | .64† |
| NA | 4 (28.6%) | 0 | |
| No. of colonies as percentage of untreated cells CFC IM 1μM | Range: [41.1, 67]; mean, 54.1; CI: [47.1, 61.1] | Range: [40.6, 92] mean=70.9; CI: [44.3, 97.4] | .16 |
| CFC IM 5μM | Range: [36, 56.6]; mean, 47.7; CI: [43.0, 52.5] | Range: [34, 64]; mean, 50.3; CI: [36.0, 64.7] | .66 |
| CFC IM 10μM | Range: [29.1, 61.3]; mean, 44.1; CI: [34.9, 53.3] | Range: [20.8, 60.3]; mean, 43.8; CI: [21.0, 66.5] | .97 |
| Time from diagnosis to IM treatment, d | Range: [7, 302]; mean, 127.4; CI: [12.0, 178.5] | Range: [13, 377]; mean, 127; CI: [-66.7, 321] | .70 |
| Qualitative features | |||
| Sokal risk score | .434‡ | ||
| High | 5 (55.6%) | 0 | |
| Intermediate | 3 (33.3%) | 3 (60%) | |
| Low | 1 (11.1%) | 1 (20%) | |
| NA | 0 | 1 (20%) | |
| Sex | .21§ | ||
| Female | 5 (55.6%) | 1 (20%) | |
| Male | 4 (44.5%) | 4 (80%) | |
| Prior interferon | .247§ | ||
| No | 8 (88.9) | 3 (60%) | |
| Yes | 1 (11.1%) | 2 (40%) | |
| Prior hydroxyurea | 1§ | ||
| No | 9 (100%) | 5 (100%) | |
| Yes | 0 | 0 | |
| Daily IM dose | .177‡ | ||
| 400 mg | 6 (66.7%) | 2 (40%) | |
| 400-600 mg | 3 (33.3%) | 1 (20%) | |
| 400-800 mg | 0 | 2 (40%) |
P values were calculated using the Welch 2-sample t test at the 5% significant level under the null hypothesis H0: mean (primary resistance) = mean (secondary resistance).
P value of mutant BCR-ABL transcript frequency was calculated after all the missing values were taken out of the sample.
Kruskal-Wallis test was used to calculate P values of ordered categorical variable for Sokal risk score and daily IM dose.
Fisher exact test was used to calculate P values of nonordered categorical variable for sex, prior interferon, and prior hydroxyurea.